Targeting cancer stem cells to suppress acquired chemotherapy resistance (Q38149736)

29 August 2017

title

Targeting cancer stem cells to suppress acquired chemotherapy resistance (English)

1 reference

29 August 2017

1 reference

neoplastic stem cells

1 reference

based on heuristic

inferred from title

author

Veronica Rodriguez-Bravo

V Rodriguez-Bravo

0 references

S J Vidal

1 reference

29 August 2017

M Galsky

series ordinal

1 reference

29 August 2017

C Cordon-Cardo

series ordinal

1 reference

29 August 2017

J Domingo-Domenech

series ordinal

1 reference

29 August 2017

language of work or name

English

0 references

publication date

7 October 2013

1 reference

29 August 2017

1 reference

29 August 2017

1 reference

29 August 2017

1 reference

29 August 2017

page(s)

4451-4463

1 reference

Timeline: Chemotherapy and the war on cancer.

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Hallmarks of Cancer: The Next Generation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Stem cell concepts renew cancer research

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Cancer stem cells: an evolving concept

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Cancer stem cell definitions and terminology: the devil is in the details.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Cancer stem cells: impact, heterogeneity, and uncertainty

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Cancer stem cells: current status and evolving complexities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

31 March 2020

Acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Stem cell gene expression programs influence clinical outcome in human leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Leukaemia stem cells and the evolution of cancer-stem-cell research.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Retention of CD34+ CML stem/progenitor cells during imatinib treatment and rapid decline after treatment with second-generation BCR-ABL inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Prospective identification of tumorigenic breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

let-7 regulates self renewal and tumorigenicity of breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Aldehyde dehydrogenase 1-positive cells in axillary lymph node metastases after chemotherapy as a prognostic factor in patients with lymph node-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

HER2 and breast cancer stem cells: more than meets the eye.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

A human colon cancer cell capable of initiating tumour growth in immunodeficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Identification and expansion of human colon-cancer-initiating cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Phenotypic characterization of human colorectal cancer stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

c-Met is a marker of pancreatic cancer stem cells and therapeutic target

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Neoadjuvant chemotherapy with gemcitabine for pancreatic cancer increases in situ expression of the apoptosis marker M30 and stem cell marker CD44.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

CD24+ Liver Tumor-Initiating Cells Drive Self-Renewal and Tumor Initiation through STAT3-Mediated NANOG Regulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Prospective identification of tumorigenic prostate cancer stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Identification of human brain tumour initiating cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Interaction of hypoxia-inducible factor-1α and Notch signaling regulates medulloblastoma precursor proliferation and fate.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

A restricted cell population propagates glioblastoma growth after chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

The hedgehog signaling pathway in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Wnt/β-catenin signaling and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Notch signaling and breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Bone morphogenetic protein-7 release from endogenous neural precursor cells suppresses the tumourigenicity of stem-like glioblastoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

A BMP7 variant inhibits the tumorigenic potential of glioblastoma stem-like cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

The tortoise and the hair: slow-cycling cells in the stem cell race

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Does tumour dormancy offer a therapeutic target?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Models, mechanisms and clinical evidence for cancer dormancy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

IFNalpha activates dormant haematopoietic stem cells in vivo.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon-γ.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Cancer epigenetics: from mechanism to therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

The role of epigenetic regulation in stem cell and cancer biology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Loss of miR-200 Inhibition of Suz12 Leads to Polycomb-Mediated Repression Required for the Formation and Maintenance of Cancer Stem Cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

MicroRNA Regulation of Cancer Stem Cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Anticancer activities of histone deacetylase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

The role of apoptosis in cancer development and treatment response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

The role of apoptosis in the regulation of hematopoietic stem cells: Overexpression of Bcl-2 increases both their number and repopulation potential

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Cytokine disbalance in common human cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Metabolic reprogramming: a cancer hallmark even warburg did not anticipate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Otto Warburg's contributions to current concepts of cancer metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Cancer metabolism: fatty acid oxidation in the limelight

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Serine, glycine and one-carbon units: cancer metabolism in full circle

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Regulation of cancer cell metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Mevalonate metabolism regulates Basal breast cancer stem cells and is a potential therapeutic target.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Metformin Decreases the Dose of Chemotherapy for Prolonging Tumor Remission in Mouse Xenografts Involving Multiple Cancer Cell Types

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Metformin selectively affects human glioblastoma tumor-initiating cell viability: A role for metformin-induced inhibition of Akt.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Stem cells and the niche: a dynamic duo.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Cancer stem cell niche: the place to be

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Accessories to the crime: functions of cells recruited to the tumor microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

A perivascular niche for brain tumor stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Therapy-resistant tumor microvascular endothelial cells contribute to treatment failure in glioblastoma multiforme.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Pancreatic stellate cells form a niche for cancer stem cells and promote their self-renewal and invasiveness.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

The perivascular niche regulates breast tumour dormancy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Identification of selective inhibitors of cancer stem cells by high-throughput screening

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets HER2-positive cancer cells and cancer stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Wnt activity defines colon cancer stem cells and is regulated by the microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

The ABC of channel regulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Tumour stem cells and drug resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

The controversial role of ABC transporters in clinical oncology.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Efficient tumour formation by single human melanoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Identification of cells initiating human melanomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Tumor-initiating cells are rare in many human tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

The epithelial-mesenchymal transition generates cells with properties of stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Temozolomide preferentially depletes cancer stem cells in glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Stage II and stage III colon cancer: treatment advances and future directions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

The prognostic role of a gene signature from tumorigenic breast-cancer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Single-cell dissection of transcriptional heterogeneity in human colon tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Expression of intercellular adhesion molecule 1 by hepatocellular carcinoma stem cells and circulating tumor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

CD133 expression in circulating tumor cells from breast cancer patients: potential role in resistance to chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.411

31 March 2020

Identifiers

DOI

10.1038/ONC.2013.411

1 reference

Dimensions Publication ID

29 August 2017

1001049720

0 references

1 reference